Hypothalamic-Pituitary-Adrenocortical System and Mood Disorders: Highlights from Mutant Mice

Neuroendocrinology

Volumn 79, Issue 1, 2004, Pages 1-12

  Müller, Marianne B ^a   Uhr, Manfred ^a   Holsboer, Florian ^a   Keck, Martin E ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adrenal steroid receptors; Anxiety; Behaviour; Blood brain barrier; Corticotropin; Corticotropin releasing hormone; Corticotropin releasing hormone receptors; Hippocampus; Molecular neuroendocrinology; Mood disorders; Mutant mice; Transgenes

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMINOGLUTETHIMIDE; ANTALARMIN; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRE RECOMBINASE; DEXAMETHASONE; DIAZEPAM; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLYCOPROTEIN P; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE (CALCIUM,CALMODULIN); UNCLASSIFIED DRUG; UROCORTIN;

ADAPTATION; ANIMAL; ANXIETY; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BEHAVIOR; BLOOD BRAIN BARRIER; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; DEPRESSION; DISEASE MODEL; DNA MODIFICATION; ENDOCRINE FUNCTION; EXPERIMENTAL MODEL; FOOD INTAKE; GENE EXPRESSION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CODE; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETICS; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; KNOCKOUT MOUSE; LIMBIC SYSTEM; MAJOR DEPRESSION; MENTAL PERFORMANCE; METABOLISM; MOOD DISORDER; MOUSE; MOUSE MUTANT; MUTAGENESIS; NEUROENDOCRINE SYSTEM; NEUROPHARMACOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, KNOCKOUT; MOOD DISORDERS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RISK FACTORS; STRESS;

EID: 0442277589     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076041     Document Type: Review

References (109)

1. Selye H: The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946;6:117-196.
2. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981;213:1394-1397.
3. Vale W, Vaughan J, Smith M, Yamamoto G, Rivier J, Rivier C: Effects of synthetic ovine corticotropin-releasing factor, glucocorticoids, catecholamines, neurohypophysial peptides, and other substances on cultured corticotropic cells. Endocrinology 1983;113:1121-1131.
4. Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1991;43:425-473.
5. Erkut ZA, Pool C, Swaab DF: Glucocorticoids suppress corticotropin- releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab 1998;83:2066-2073.
6. Belanoff JK, Gross K, Yager A, Schatzberg AF: Corticosteroids and cognition. J Psychiatr Res 2001;35:127-145.
7. Korte SM: Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 2001;25:117-142.
8. 8de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
9. Chrousos PW, Gold PW: The concepts of stress and stress system disorders: Overview of physical and behavioural homeostasis. JAMA 1992;267:1244-1252.
10. McEwen BS: The neurobiology of stress: From serendipity to clinical relevance. Brain Res 2000;886:172-189.
11. Holsboer F: Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 2001;62:77-91.
12. Sloviter R, Valiquette G, Abrams G, Ronk EC, Sollas AI, Neubort SL: Selective loss of hippocampal granule cells in the mature rat brain after adrenalectomy. Science 1989;243:535-538.
13. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE: Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry 1999;46:1595-1602.
14. Müller MB, Lucassen PJ, Hoogendijk WG, Holsboer F, Swaab DF: Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 2001;14:1603-1612.
15. Lucassen PJ, Müller MB, Holsboer F, Bauer J, Holtrop A, Wouda J, Hoogendijk WJ, de Kloet ER, Swaab DF: Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001;158:453-468.
16. Lehnert H, Schulz C, Dieterich K: Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: The role of the locus coeruleus. Neurochem Res 1998;23:1039-1052.
17. Van Bockstaele EJ, Colago EE, Valentino RJ: Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: Substrate for the co-ordination of emotional and cognitive limbs of the stress response. J Neuroendocrinol 1998;10:743-757.
18. Swanson LW, Sawchenko PE, Rivier J, Vale WW: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 1983;36:165-186.
19. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-292.
20. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE: Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-2848.
21. Hsu SY, Hsueh AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001;7:605-611.
22. Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002;2:23-33.
23. Sillaber I, Rammes G, Zimmermann S, Mahal B, Zieglgänsberger W, Wurst W, Holsboer F, Spanagel R: Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science 2002;296:931-933.
24. Dunn AJ, Berridge CW: Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15:71-100.
25. Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A: Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept 1995;59:229-239.
26. Keck ME, Holsboer F: Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 2001;22:835-844.
27. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF: Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60:436-444.
28. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF: Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996;53:137-143.
29. Heuser I, Yassouridis A, Holsboer F: The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28:341-356.
30. Holsboer F: The rationale for the corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999;33:181-214.
31. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
32. Keck ME, Welt T, Müller MB, Uhr M, Ohl F, Wigger A, Toschi N, Holsboer F, Landgraf R: Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003;28:235-243.
33. Keck ME, Wigger A, Welt T, Müller MB, Gesing A, Reul JM, Holsboer F, Landgraf R, Neumann ID: Vasopressin mediated the response of the combined dexamethasone/CRH test in hyperanxious rats: Implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002;26:94-105.
34. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 1996;17:187-205.
35. Nemeroff CB, Owens MJ: Treatment of mood disorders. Nat Neurosci 2002;5:1068-1070.
36. Holsboer F, Lauer CJ, Schreiber W, Krieg JC: Altered hypothalamic- pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995;62:340-347.
37. Modell S, Yassouridis A, Huber J, Holsboer F: Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997;65:216-222.
38. Müller MB, Landgraf R, Sillaber I, Kresse AE, Keck ME, Zimmermann S, Holsboer F, Wurst W: Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 2000;141:4262-4269.
39. Detera-Wadleigh SD, Berrettini WH, Goldin LR, Martinez M, Hsieh WT, Hoehe MR, Encio IJ, Coffman D, Rollins DY, Muniec D: A systematic search for a bipolar predisposing locus on chromosome 5. Neuropsychopharmacology 1992;6:219-229.
40. Mirow AL, Kristbjanarson H, Egeland JA, Shilling P, Helgason T, Gillin JC, Hirsch S, Kelsoe JR: A linkage study of distal chromosome 5q and bipolar disorder. Biol Psychiatry 1994;36:223-229.
41. Morissette J, Villeneuve A, Bordeleau L, Rochette D, Laberge C, Gagné B, Laprise C, Bouchard G, Plante M, Gobeil L, Shink E, Weissenbach J, Barden N: Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogenous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 1999;88:567-587.
42. Moutsatsou P, Tsolakidou A, Trikkas G, Troungos C, Sekeris CE: Glucocorticoid receptor alpha and beta isoforms are not mutated in bipolar affective disorder. Mol Psychiatry 2000;5:196-202.
43. Syvanen AC: Accessing genetic variation: Genotyping single nucleotide polymorphisms. Nat Rev Genet 2001;2:930-942.
44. Cowan WM, Kopnisky KL, Hyman SE: The human genome project and its impact on psychiatry. Annu Rev Neurosci 2002;25:1-50.
45. van Rossum EF, Koper JW, Huizenga NA, Uitterlinden AG, Janssen JA, Brinkmann AO, Grobbee DE, de Jong FH, van Duyn CM, Pols HA, Lamberts SW: A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002;51:3128-3134.
46. DeRijk RH, Schaaf M, de Kloet ER: Glucocorticoid receptor variants: Clinical implications. J Steroid Biochem Mol Biol 2002;81:103-122.
47. Murphy BE: Antiglucocorticoid therapies in major depression: A review. Psychoneuroendocrinology 1997;22:125-132.
48. McQuade R, Young AH: Future therapeutic targets in mood disorders: The glucocorticoid receptor. Br J Psychiatry 2000;177:390-395.
49. Ravaris CL, Sateia MJ, Beroza KW, Noordsy DL, Brinck-Johnsen T: Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 1988;45:966-967.
50. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J: Antiglucocorticoid treatment of depression: Double-blind ketoconazole. Biol Psychiatry 1999;45:1070-1074.
51. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, Heninger GR, Price LH: Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 1999;19:466-470.
52. Belanoff JK, Rothschild AJ, Cassidy F, De Battista C, Baulieu EE, Schold C, Schatzberg AF: An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386-392.
53. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R: The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001;13:373-380.
54. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW: Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioural, neuroendocrine, and autonomic responses to stress. Proc Acad Natl Sci USA 2000;97:6079-6084.
55. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F: Effects of the high-affinity corticotropin-releasing hormone receptor antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000;34:171-181.
56. Müller U: Ten years of gene targeting: Targeted mouse mutants, from vector design to phenotype analysis. Mech Dev 1999;82:3-21.
57. + metabolism. Proc Natl Acad Sci USA 1998;95:9424-9429.
58. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schütz G: Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995;9:1608-1621.
59. Moran TH, Reeves RH, Rogers D, Fisher E: Ain't misbehavin' - it's genetic. Nat Genet 1996;12:115-116.
60. Lewandoski M: Conditional control of gene expression in the mouse. Nat Rev Genet 2001;2:743-755.
61. Nagy A: Cre recombinase: The universal reagent for genome tailoring. Genesis 2000;26:99-109.
62. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G: Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 1999;23:99-103.
63. Contarino A, Gold LH: Targeted mutations of the corticotropin-releasing factor system: Effects on physiology and behavior. Neuropeptides 2002;36:103-116.
64. Müller MB, Keck ME: Genetically engineered mice for studies of stress-related clinical conditions. J Psychiatr Res 2002;36:53-76.
65. Müller MB, Holsboer F, Keck ME: Genetic modification of corticosteroid receptor signalling: Novel insights into pathophysiology and treatment strategies of human affective disorders. Neuropeptides 2002;36:117-131.
66. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W: Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992;130:3378-3386.
67. Heinrichs SC, Min H, Tamraz S, Carmouche M, Boehme SA, Vale WW: Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 1997;22:215-224.
68. van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T: Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 2002;15:2007-2015.
69. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW: Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior. J Neurosci 1994;14:2579-2584.
70. Groenink L, Dirks A, Verdouw PM, Schipholt MI, Veening JG, van der Gugten J, Olivier B: HPA axis dysregulation in mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 2002;51:875-881.
71. Dirks A, Groenink L, Bouwknecht JA, Hijzen TH, van der Gugten J, Ronken E, Verbeek JS, Veening JG, Dederen PJ, Korosi A, Schoolderman LF, Roubos EW, Olivier B: Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci 2002;16:1751-1760.
72. Dirks A, Groenink L, Schipholt MI, van der Gugten J, Hijzen TH, Geyer MA, Olivier B: Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 2002;51:583-590.
73. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998;19:162-166.
74. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikijan LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998;20:1093-1102.
75. Preil J, Müller MB, Gesing A, Reul JM, Sillaber I, van Gaalen M, Landgrebe J, Stenzel-Poore M, Holsboer F, Wurst W: Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 2001;142:4946-4955.
76. Korte SM, Korte-Bouws GA, Koob GF, De Kloet ER, Bohus B: Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety. Pharmacol Biochem Behav 1996;54:261-267.
77. Minichiello L, Korte M, Wolfer DP, Kühn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R: Essential role of trkB receptors in hippocampus-mediated learning. Neuron 1999;24:401-414.
78. Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste S, Kühn R, Reul JM, Holsboer F, Wurst W: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 2003;6:1100-1107.
79. Cole JC, Rodgers RJ: Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 1995;52:473-478.
80. Rodgers JI, Dalvi A: Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 1997;21:801-810.
81. Cole TJ, Myles K, Purton JF, Brereton PS, Solomon NM, Godfrey DI, Funder JW: GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol 2001;173:193-202.
82. Oitzl MS, de Kloet ER, Joels M, Schmid W, Cole TJ: Spatial learning deficits in mice with a targeted glucocorticoid receptor gene disruption. Eur J Neurosci 1997;9:2284-2296.
83. Weiss JM, McEwen BS, Silva MT, Kalkut MF: Pituitary-adrenal influences on fear responding. Science 1969;163:197-199.
84. Plihal W, Krug R, Pietrowski R, Fehm HL, Born J: Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendocrinology 1996;21:515-523.
85. Beato M, Herrlich P, Schutz G: Steroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-857.
86. Trapp T, Holsboer F: Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trends Pharmacol Sci 1996;17:145-149.
87. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-541.
88. Oitzl MS, Reichardt HM, Joels M, de Kloet ER: Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. Proc Natl Acad Sci USA 2001;98:12790-12795.
89. Joels M, de Kloet ER: Mineralocorticoid and glucocorticoid receptors in the brain: Implications for ion permeability and transmitter systems. Prog Neurobiol 1994;43:1-36.
90. Karst H, Karten YJ, Reichardt HM, de Kloet ER, Schutz G, Joels M: Corticosteroid actions in hippocampus require DNA binding of glucocorticoid receptor homodimers. Nat Neurosci 2000;3:977-978.
91. Wei Q, Schafer GL, Hebda-Bauer E, Shieh KR, Watson S, Seasholtz A, Akil H: Tissue-specific overexpression of the glucocorticoid receptor in the brain. Soc Neurosci Abstr 2001.
92. Joels M, de Kloet ER: Control of neuronal excitability by corticosteroid hormones. Trends Neurosci 1992;15:25-30.
93. Lupien SJ, McEwen BS: The acute effects of corticosteroids on cognition: Integration of animal and human model studies. Brain Res Brain Res Rev 1997;24:1-27.
94. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE: The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989;9:1346-1350.
95. Schinkel AH: Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36:9-13.
96. Uhr M, Steckler T, Yassouridis A, Holsboer F: Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000;22:380-387.
97. Uhr M, Grauer MT, Holsboer F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54:840-846.
98. Uhr M, Grauer MT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003;37:179-185.
99. Devault A, Gros P: Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990;10:1652-1663.
100. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ: Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 2002;43:1318-1323.
101. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F: Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998;71:705-715.
102. van de Vrie W, Marquet RL, Stoter G, De Bruijn EA, Eggermont AM: In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 1998;35:1-57.
103. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER: Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998;139:1789-1793.
104. Uhr M, Holsboer F, Müller MB: Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 2002;14:753-759.
105. Müller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F, Uhr M: ABCB1-(MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: Implications for affective disorder. Neuropsychopharmacology 2003;28:1991-1999.
106. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphism of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Acad Natl Sci USA 2000;97:3473-3478.
107. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
108. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W: Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 2000;36:66-74.
109. Pariante CM, Hye A, Wiliamson R, Makoff A, Lovestone S, Kerwin RW: The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 2003;28:1553-1561.